Don Benson M MD, PhD

Don Benson M MD, PhD
Assoc Professor - ClinicalCollege of Medicinebenson.236@osu.edu
A445 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-366-3802Fax: (614) 293-7526
  • Molecular Carcinogenesis and Chemoprevention

General Research Interest

Natural Killer cell immunotherapy

Research Description

Our laboratory and clinical research programs seek to develop novel treatments for cancer that harness and enhance the immune system’s ability to detect and kill cancer cells.  Natural killer cells, one type of immune cell in the body, are capable of killing cancer cells and much of the research we do focuses on augmenting or recovering the function of these cells to fight cancer.  Our research has been supported by the National Cancer Institute, CLL Global Research Foundation, the American Cancer Society, the American Society of Clinical Oncology, Multiple Myeloma Research Foundation, Multiple Myeloma Opportunities for Research and Education, and the Ohio State University / Nationwide Children’s Hospital Collaborative Research Award.

Transinstitutional Work

We collaborate with members of the blood and marrow transplant program as well as cancer researchers at Nationwide Children’s Hospital (Columbus OH), as well as researchers in Marseille, France, Copenhagen, Denmark, Yavne, Israel, and a number of other sites in the United States, including researchers at the University of Tennesee (Knoxville, TN), MD Anderson Cancer Center (Houston TX), the Mayo Clinic (Rochester MN), and Karmanos Cancer Center (Detroit MI).  Here at Ohio State, we do research with members of the Pharmacology program, molecular genetics and immunology, and pathology.  We have nearly two dozen open clinical trials for patients with cancer and in the laboratory, we are working on over 5 completely novel, promising cancer therapies for future use in the clinic.

Current Publications

  • Salem G, Ruppert AS, Elder P, Hofmeister Craig C, Benson Don M, Penza S, Andritsos Leslie, Klisovic R, Vasu S, Blum William, Devine Steven M, Jaglowski Samantha, Efebera Yvonne ALower Dose of Antithymocyte Globulin (ATG) does not increase Graft-vs-Host Disease (GVHD) in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT).Leuk Lymphoma in press 8/28/2014
  • Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LAThe hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.Bone Marrow Transplant in press 7/28/2014
  • Hofmeister CC, Satoskar A, Nadasdy T, Nadasdy G, Benson DM, Gillmore JD, Hawkins PN, Rowczenio D, Efebera YA, Sturm A, Baack ECNovel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred.Amyloid 21 110-2 6/1/2014
  • Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RRIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Blood 123 3390-7 5/29/2014
  • Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND, Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman SA phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).Blood 123 3398-405 5/29/2014
  • Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE, Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston NDIdelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Blood 123 3406-13 5/29/2014
  • Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SMAprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.Support Care Cancer in press 5/17/2014
  • Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri FCirculating miRNA markers show promise as new prognosticators for multiple myeloma.Leukemia in press 5/12/2014
  • Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA, Alliance for Clinical Trials in OncologyRecombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.Cancer 120 1010-7 4/1/2014
  • Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu JCS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.Leukemia 28 917-27 4/1/2014
  • Benson DM Jr, Caligiuri MAKiller immunoglobulin-like receptors and tumor immunity.Cancer Immunol Res 2 99-104 2/1/2014
  • Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JCA phase I trial of flavopiridol in relapsed multiple myeloma.Cancer Chemother Pharmacol 73 249-57 2/1/2014
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol 89 19-24 1/1/2014
  • Yasmeen R, Meyers JM, Alvarez CE, Thomas JL, Bonnegarde-Bernard A, Alder H, Papenfuss TL, Benson DM Jr, Boyaka PN, Ziouzenkova OAldehyde dehydrogenase-1a1 induces oncogene suppressor genes in B cell populations.Biochim Biophys Acta 1833 3218-27 12/1/2013
  • Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri FCharacterization of multiple myeloma vesicles by label-free relative quantitation.Proteomics 13 3013-29 10/1/2013
  • Roth RM, Benson D, Hebert LA, Bissell MG, Satoskar AA, Nadasdy T, Brodsky SVProgressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.Arch Pathol Lab Med 137 1304-8 9/1/2013
  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48 1212-7 9/1/2013
  • Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YAEarly versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Leuk Lymphoma 54 1658-64 8/1/2013
  • Burkart J, Benson DM JrWhen first line therapy for AA-amyloidosis secondary to rheumatoid arthritis fails: a correspondence.Joint Bone Spine 80 229-30 3/1/2013
  • Benson DM JrCan NKT cells extinguish smoldering myeloma?Blood 121 418-20 1/17/2013
  • Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, Dombret H, Olive DA phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.Blood 120 4317-23 11/22/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu